Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 mil
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Scientists at the National Physical Laboratory (NPL) have ... that provides structural support to cells to aid growth ... regenerative medicine. The extracellular matrix (ECM) provides the ... all biological tissues. It is a complex nano-to-microscale structure ...
... be coming soon to an ocean near you. Sensorbots ... to open a new chapter in the notoriously challenging ... devices are being designed and developed in the laboratory ... of the Center for Biosignatures Discovery Automation at Arizona ...
... hatcheries on salmon is so profound that in just one ... prosper in the hatchery environment, at the cost of their ... These findings, published this week in Proceedings of the ... and natural selection that surprised researchers. They confirmed that ...
Cached Biology News:Sensing the deep ocean 2Sensing the deep ocean 3Sensing the deep ocean 4Sensing the deep ocean 5Evolution at warp speed: Hatcheries change salmon genetics after a single generation 2Evolution at warp speed: Hatcheries change salmon genetics after a single generation 3